Search This Blog

Monday, February 10, 2020

FDA accepts Aquestive’s Libervant NDA; shares up 6% premarket

The FDA accepts for review Aquestive Therapeutics’ (NASDAQ:AQST) marketing application seeking approval of Libervant (diazepam) Buccal Film for the management of seizure clusters.
The agency’s action date is September 27.
Shares up 6% premarket on modest volume.
https://seekingalpha.com/news/3539984-fda-accepts-aquestives-libervant-nda-shares-up-6-premarket

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.